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Atopic dermatitis (AD) is a chronically recurrent inflammato-
ry skin disorder characterized by pruritus, a specific distribu-
tion, and a family history. It has recently been reported that the 
incidence of AD has increased in Korea.
1,2 Pruritus, sleep loss, 
dietary restrictions, and psychosocial factors significantly de-
crease the quality of life for AD patients.
3,4 Recently, the Europe-
an Academy of Allergy and Clinical Immunology and the Amer-
ican Academy of Allergy, Asthma, and Immunology published 
the PRACTALL consensus report for the diagnosis and treat-
ment of AD in children and adults.
5 The report suggests a step-
wise management that includes the addition of multiple thera-
peutic agents on the basis of the disease severity.
The PRACTALL consensus report defines severe or recalcitrant 
AD as AD that cannot be controlled with topical treatment.
6 In 
the 2009 Korean Work Group Report on the treatment of severe/
recalcitrant AD, severe AD is defined as AD with a SCORAD in-
dex higher than 50 and that cannot be controlled with conven-
tional treatment,
7 while the 2008 Guideline of Atopic Dermatitis 
in Korean Children defines severe AD by a SCORAD index high-
er than 40.
8 Specific criteria for the definition of recalcitrant and 
severe AD are necessary.
For the management of severe AD, the PRACTALL consensus 
report recommends systemic therapy such as antimicrobial 
treatment, systemic corticosteroids, cyclosporin A, azathioprine, 
anti-histamines, phototherapy, and immunotherapy. Several 
reports, including the 2009 Korean Work Group Report, have 
described intravenous immunoglobulin (IVIg) treatment as one 
of various immunoregulatory treatments. Nevertheless, this 
treatment was not included in the PRACTALL report.
7,9,10
IVIg treatment displays immunomodulatory and anti-inflam-
matory properties, and its effectiveness in several immune-me-
diated conditions such as Kawasaki disease and idiopathic 
thrombocytopenic purpura has been demonstrated.
11 IVIg is 
considered a candidate for the treatment of AD because of its 
ability to downregulate T-cell function, particularly interleu-
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kin-4 production.
12,13 A small number of observations on the ef-
ficiency of IVIg in AD have been reported, but prospective and 
randomized studies for its clinical efficiency in childhood AD 
are sparse. A randomized, placebo-controlled prospective study 
in childhood AD patients is therefore required.
14
Jee et al.
14 recently reported therapeutic effects of IVIg in child-
hood AD; however, this study involved moderate to severe AD 
patients, and it did not include severe AD patients because the 
disease severity might have affected the treatment results. Fur-
ther randomized studies with strict criteria for recalcitrant/se-
vere AD are warranted. In addition, the IVIg effective dose, the 
dosing interval for initiation and maintenance, the identifica-
tion of biomarkers (e.g., ECP, ICAM-1, and IL-5/INF-gamma) to 
determine efficiency, and clear criteria for IVIg indications all 
require consideration.
Currently, we lack evidence-based data supporting the use of 
IVIg and other immunomodulators in childhood AD. Before 
IVIg can be recommended, its cost-benefit ratio, course, dura-
tion, and adverse reactions compared with alternative thera-
peutic options must be determined. The effects of novel thera-
pies such as IVIg for recalcitrant/severe AD patients should be 
verified through repeated research and numerous research dis-
cussions.
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